Pricing Log in Create free account
Friday 6 November 2026 Export CTEV’s income statement to Excel — free account

Claritev Corporation

CTEV Healthcare Health Information Services

Claritev Corporation’s revenue for fiscal 2025 (year ended December 2025) was $965.4 million, up 3.74% from fiscal 2024.

Revenue
+6.59%
EPS
+8.40%
Free cash flow
+49.1%
Total debt
+0.97%

Quarter to June 2026, against a year earlier

22.88 2.66 +13.16%
Market cap
$342.7M
P/E
0.0×
Fwd P/E
−1.6×
Dividend yield
—
F-score
5/9
Altman Z
−0.40
Beneish M
−2.59
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 3.33
Sold, $m 1.06
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 2 3 — 3 1 — 1 — 1 —
Sell — — — — — — — — 2 1 1 —
Insider Ownership 48.78%

Capital & Financial Ratios $m

Size
Market Cap 342.68
Revenue ttm 994.67
Net income ttm (283.11)
Free cash flow ttm (17.92)
Net debt Q 4,645.18
Valuation
P/E 0.00
Forward P/E (1.59) (negative: loss-making)
Price / sales 0.39
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 1.00 (below 1: weak)
Debt / equity Q (16.23) (negative: negative equity)
Interest coverage Q 0.23
Growth
Revenue growth Q +6.59% (above 0%: growing)
Operating income growth Q +41.21% (above 0%: growing)
EPS, this year +12.62%
EPS, next year A +10.51%
Revenue, next year A +5.03%
EPS, past 5 yrs —
EPS, next 5 yrs A +11.90%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.1×, against a ten-year median of 5.5×; over the ten years it ranged from 4.6× in 2022 to 10.9× in 2021.
P/S against its own 10 years 15.04%
10-year low 10-year high
EV/Sales against its own 10 years 20.29%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 81 30 28 28
Receivables 77 90 128 131
Inventory — — — —
Other 12 36 36 46
194 176 224 236
2023 2024 2025 Q'26
Payables 20 86 60 57
ST’ Debt 13 13 15 15
Other — — — —
167 214 261 238

Compound Annual Growth %

10y 5y 3y
Sales — 0.58% (3.66%)
Cash Flow — (20.84%) (31.95%)
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −4.10 Actual −3.49

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −3.12 −4.07 Miss by 0.95
Q4 FY25 −3.96 −4.88 Miss by 0.92
Q1 FY26 −3.81 −4.41 Miss by 0.60
Q2 FY26 −4.10 −3.49 Beat by 0.61
Q3 FY26 −3.68 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (4.41) (3.49) — — —
’25 (4.38) (3.81) (4.23) (4.88) (17.30)
’24 (33.20) (35.60) (24.25) (8.49) (101.92)
’23 0.01 (2.40) (1.60) (2.00) (5.60)
’22 2.80 0.80 1.20 (40.80) (36.00)
’21 2.80 (2.80) 4.80 1.60 6.40
’20 (0.25) (5.41) (27.75) (10.80) (44.80)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 245 257 — — —
’25 231 242 246 247 965
’24 235 233 230 232 931
’23 237 238 243 244 962
’22 298 290 250 241 1,080
’21 255 276 288 298 1,118
’20 252 207 224 255 938
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (46) 93 — — —
’25 (30) 61 20 66 117
’24 50 18 73 (33) 108
’23 64 8 72 28 172
’22 195 41 109 28 372
’21 171 33 167 33 405
’20 147 44 140 45 377
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (93) 55 — — —
’25 (69) 37 (16) 36 (12)
’24 19 (7) 41 (64) (11)
’23 41 (24) 50 (4) 63
’22 170 22 88 2 283
’21 153 15 147 6 320
’20 130 27 126 24 307
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 1,041 983 938 1,118 1,080 962 931 965 995 (1.1%) 1,014 1,063 1,114 +4.9%
Gross margin, % — — 85.64 84.78 66.02 84.32 81.10 75.51 74.27 73.75 72.97 (11.9) pt
EBT — — 44 11 (547) 135 (561) (107) (1,771) (373) (370) n/m
EBT margin, % — — 4.26 1.07 (58.32) 12.12 (51.93) (11.13) (190.27) (38.64) (37.16) (42.9) pt
Net income — 0 36 10 (521) 102 (573) (92) (1,646) (284) (283) n/m
Per share, $
Per share, $ Revenue — — 100.16 94.58 79.68 68.67 67.60 59.62 57.63 58.74 58.63 (7.3%)
Earnings — — 3.49 0.93 (44.80) 6.40 (36.00) (5.60) (101.92) (17.30) (17.01) n/m
Cash flow — — 28.13 27.36 32.06 24.87 23.31 10.65 6.66 7.14 7.84 (17.8%)
Capex — — (6.12) (6.39) (6.02) (5.20) (5.62) (6.75) (7.32) (7.89) (8.90) +3.7%
Free cash flow — — 22.01 20.97 26.05 19.67 17.69 3.90 (0.65) (0.75) (1.06) n/m
Book value — — 0.00 191.02 217.33 144.06 112.10 105.97 5.20 (10.17) (16.97) n/m
Shares, m — — 10 10 12 16 16 16 16 16 17 +6.8%
Valuation, ×
Valuation, × P/E — — 972.00 972.00 0.00 27.69 0.00 0.00 0.00 0.00 0.00 246.5
P/S — — 0.00 0.00 4.01 2.58 0.62 0.92 0.26 0.73 0.39 1.1
P/B — — 3.78 3.78 1.47 1.23 0.37 0.52 2.84 0.00 0.00 1.7
EV/Sales — — 0.00 0.00 8.77 6.79 4.70 5.56 5.08 5.46 5.06 4.5
EV/FCF — — 0.00 0.00 26.81 23.71 17.97 85.07 (450.36) (429.21) (280.82) (90.8)
Cash, $m
Cash, $m Operating cash flow — — 292 284 377 405 372 172 108 117 133 (12.2%)
Capex — — (64) (66) (71) (85) (90) (109) (118) (130) (151) +10.7%
Free cash flow — — 229 218 307 320 283 63 (11) (12) (18) n/m
Balance, $m
Balance, $m Working capital — — — 30 96 177 271 27 (38) (37) (1) n/m
Net debt — — — 5,385 4,459 4,704 4,415 4,464 4,493 4,567 4,645 (2.7%)
Shareholders’ equity — — — 1,985 2,558 2,345 1,791 1,709 84 (167) (288) n/m
Returns, %
Returns, % ROA — — 0.00 0.23 (6.26) 1.24 (7.35) (1.28) (27.17) (5.66) (5.76) (5.7) pt
ROIC — — 0.00 3.12 (1.17) 3.42 (3.65) 1.64 (18.98) 0.41 0.47 +0.4 pt
ROE — — 0.00 0.43 (22.92) 4.16 (27.71) (5.24) (183.57) 683.76 172.76 +683.8 pt
People
People Employees — — — — 2,000 2,400 2,500 2,800 2,700 3,000 — +8.4%
Revenue/emp, $m — — 0.00 0.00 0.47 0.47 0.43 0.34 0.34 0.32 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Claritev Corporation vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NRC National Research Corporation $563.6M 87.6× 61.1× +10.95% (above 0%: growing) +22.22% (above 0%: growing) −31.38% (below 0%: shrinking) 59.95% 23.20% Compare
SOPH SOPHiA GENETICS SA $563.6M — (loss-making) — (loss-making) +24.69% (above 0%: growing) n/m −1.87% (below 0%: shrinking) 65.66% (73.45%) Compare
EVH Evolent Health, Inc $513.3M — (loss-making) — (loss-making) +51.27% (above 0%: growing) n/m +179.84% (above 0%: growing) 12.19% (0.85%) Compare
CARL Carlsmed, Inc. $418.3M — (loss-making) — (loss-making) +56.75% (above 0%: growing) n/m −6.84% (below 0%: shrinking) 76.78% (58.27%) Compare
CTEV Claritev Corporation $342.7M — (loss-making) — (loss-making) +6.59% (above 0%: growing) n/m +49.10% (above 0%: growing) 73.72% 9.09%
SPOK Spok Holdings, Inc. $245.9M 12.9× 16.2× −2.56% (below 0%: shrinking) +190.31% (above 0%: growing) +61.57% (above 0%: growing) 79.66% 17.08% Compare
AMWL American Well Corporation $208.5M — (loss-making) — (loss-making) −12.96% (below 0%: shrinking) n/m +21.98% (above 0%: growing) 52.99% (23.79%) Compare
DH Definitive Healthcare Corp. $163.7M — (loss-making) — (loss-making) −8.99% (below 0%: shrinking) n/m −32.60% (below 0%: shrinking) 77.27% (9.09%) Compare
OPRX OptimizeRx Corp. $163.3M 35.8× 41.7× −29.77% (below 0%: shrinking) n/m +89.86% (above 0%: growing) 76.51% (0.43%) Compare
Median of peers $332.1M 35.8× 41.7× +4.20% — +10.06% 71.09% (4.97%)

All 44 Health Information Services stocks →

Pay and ownership Proxy statement filed 20 March 2026

Ownership

Directors and executive officers, together 7.40%
H&F Investors 22.90%
Ares Management 11.00%
The Public Investment Fund of the Kingdom of Saudi Arabia 9.10%
Arini Capital Management 8.90%
GIC Investor 7.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Claritev Corporation (CTEV) Latest News

29 Oct

Impact 4 · · GlobeNewswire

28 Oct

Impact 3 · · Zacks

15 Oct

Impact 3 · · GlobeNewswire

22 Sep

Impact 4 · · Business Wire

7 Sep

Impact 3 ·

17 Aug

Impact 3 ·

14 Aug

Impact 3 · · The Motley Fool transcript

13 Aug

Impact 3 ·

8 Aug

Impact 3 · · Moby transcript

7 Aug

Impact 4 · transcript
Impact 4 · · InvestorsHub
Impact 3 · · MarketBeat
Impact 3 ·
Impact 3 ·

30 Jul

Impact 4 ·

28 Jul

Impact 3 ·

16 Jul

Impact 3 ·

14 Jul

Impact 4 ·
Impact 4 ·
Impact 4 ·

9 Jul

Impact 3 ·

13 May

Impact 4 · · Business Wire

9 May

Impact 3 · · MarketBeat

7 May

Impact 4 · · Moby
Impact 4 · · Business Wire
Impact 3 ·

21 Apr

Impact 3 ·

20 Apr

Impact 4 ·

8 Mar

Impact 4 · · Simply Wall St.

24 Feb

Impact 4 · · GuruFocus.com
stockrow.com/CTEV · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com